Trust Company of Vermont’s 10x Genomics TXG Stock Holding History

Trust Company of Vermont’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-14	Closed	-$272	–	1109
2024 Q2	$272	Hold	14	–	–	﹤0.01%	868
2024 Q1	$525	Hold	14	–	–	﹤0.01%	816
2023 Q4	$783	Hold	14	–	–	﹤0.01%	719
2023 Q3	$578	Hold	14	–	–	﹤0.01%	781
2023 Q2	$782	Hold	14	–	–	﹤0.01%	791
2023 Q1	$781	Hold	14	–	–	﹤0.01%	834
2022 Q4	$510	Hold	14	–	–	﹤0.01%	836
2022 Q3	$0	Hold	14	–	–	﹤0.01%	1028
2022 Q2	$1K	Buy	+14	New	+$726	﹤0.01%	882
2022 Q1	–	Sell	-14	Closed	-$2K	–	706
2021 Q4	$2K	Buy	+14	New	+$2.14K	﹤0.01%	780
2021 Q3	–	Sell	-14	Closed	-$3K	–	679
2021 Q2	$3K	Hold	14	–	–	﹤0.01%	731
2021 Q1	$3K	Hold	14	–	–	﹤0.01%	710
2020 Q4	$2K	Buy	+14	New	+$2.03K	﹤0.01%	725

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Trust Company of Vermont's TXG Position: Q3 2024 in Review

Trust Company of Vermont sold out of 10x Genomics (TXG) in Q3 2024, closing a stake of 14 shares — an estimated $272 sold.

Trust Company of Vermont first reported a position in TXG in Q4 2020 and held it in 13 quarters. The position peaked at $3K in Q2 2021. 266 funds tracked by Wall St. Rank hold TXG as of Q3 2024.

Trust Company of Vermont reported no remaining 10x Genomics position as of Q3 2024 after selling out during the quarter.
Trust Company of Vermont sold 14 10x Genomics shares in Q3 2024, an estimated $272.
Trust Company of Vermont first reported a position in 10x Genomics in Q4 2020 and held it in 13 quarters.
Trust Company of Vermont's 10x Genomics position peaked at $3K in Q2 2021.
266 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2024.

Based on Trust Company of Vermont's 13F filing for Q3 2024, filed 16 Oct 2024.